Name Department/Institute Therapeutic area Project title
Svetlana Reilly Cardiovascular Medicine Cardiovascular medicine Screening for hit compounds for the therapeutic purpose of treating cardiac fibrosis
Ben Davis Chemistry Anti-infectives Development of novel-mode anti-infectives
Gustavo Arruda Bezerra SGC Anti-infectives Screening and characterization of small molecules targeting proteases for antibiotic development
Nicole Zitzmann Biochemistry Anti-infectives Towards a novel class of broad-spectrum antivirals
Shoumo Bhattacharya Wellcome Trust Centre for Human Genetics Cardiovascular medicine Evasins as chemokine traps for myocarditis
Claus Nerlov Weatherall Institute Oncology Development of inhibitors targeting retrograde signalling in cancer
Irina Udalova Kennedy Institute Inflammation & Immunity Developing inhibitor tool compounds to investigate the IRF5 pathway and inflammation
Ivan Ahel Sir William Dunn School of Pathology Anti-infectives Development of potent antibacterials against a novel toxin-antitoxin system
Kristijan Ramadan Oncology Oncology Development of a first in class protease inhibitor in the field of oncology
Ming Lei Pharmacology Cardiovascular medicine Development of a small molecule kinase activator as a drug candidate for the management of heart failure and cardiac hypertrophy
Paul Brennan Nuffield Department of Medicine Oncology Inhibition of a Histone Methyl Transferase for the treatment of chemotherapy induced peripheral neuropathy
Beth Psaila/Adam Mead Weatherall Institute Oncology Megakaryocytes as novel cellular targets for myelofibrosis, a severe bone marrow disorder
David Vaux Sir William Dunn School of Pathology Neuroscience Amyloid oligomerisation inhibitors and microglial stabilisation
Cassandra Adams SGC, Nuffield Department of Clinical Medicine Musculoskeletal Pre-clinical development of a bromodomain inhibitor for the treatment of Dupuytren’s disease
Richard Williams Kennedy Institute Inflammation & Immunity Targeting the kynurenin pathway for the treatment of rheumatoid arthritis
Kim Midwood Kennedy Institute Inflammation & Immunity Targeting endogenous inflammatory triggers to treat chronic inflammation
Kilian Huber Nuffield Department of Medicine Oncology Identification of first-in-class small molecule inhibitors as potential immunooncology therapeutics
Yoshi Itoh Kennedy Institute Musculoskeletal Development of stereotactic modifiers selective for the collagenolytic activity of a protease
Mark Coles/Chris Buckley Kennedy Institute Inflammation & Immunity Inhibiting tissue damage in rheumatoid arthritis through a first in class therapeutic antibody
Alison Simmons Weatherall Institute Inflammation & Immunity Therapeutic targeting of a novel cytokine in Inflammatory Bowel Disease 

Lab282 Partners